These findings indicated that early-stage renal damage is a risk factor associated with the incidence of CAP in patients with T2DM, and serum LCN-2 may be a biomarker that is related to the early-stage renal damage and pathogenesis of CAP in patients with T2DM. The gene discussed is LCN2; the disease is type 2 diabetes mellitus.